ArsenalBio Stock
HealthTechLooking to sell ArsenalBio stock or options?
ArsenalBio is a pioneering cell therapy company that aims to innovate, develop, and commercialize potential curative immune cell therapies. The company leverages a comprehensive research and development platform that helps create multifunctional T-cell treatments. This is made possible through the strategic insertion of large synthetic DNA sequences. ArsenalBio thus provides clinicians with the most advanced autologous T-cell therapies to combat cancer.
Kenneth Drazan, Green Sands Equity, UCSF Foundation Investment Company, Byers Capital, Milky Way Investments Group, Triatomic Capital, University of California, Parker Institute for Cancer Immunotherapy, ARCH Venture Partners, Waycross Ventures, Bristol-Myers Squibb, Osage University Partners, NVentures (Santa Clara), Kleiner Perkins, Emerson Collective, Westlake Village BioPartners, Hitachi Ventures, Sixth Street Partners, Luma Group, Rock Springs Capital, Regeneron Ventures, SoftBank Investment Advisers, Euclidean Capital.